Evidence map›Paper›PMID 26902202›Full record

ArticleEMBO molecular medicine2016

Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability.

Andrew Dauber, María T Muñoz-Calvo, Vicente Barrios, Horacio M Domené, Soren Kloverpris, Clara Serra-Juhé, Vardhini Desikan, Jesús Pozo, Radhika Muzumdar, Gabriel Á Martos-Moreno and 11 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 209 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Review
  5. Idiopathic short stature in the genomic era: a focused narrative review of genotype-phenotype correlation, selective neuroimaging, IGF-1 biology, and growth hormone responsiveness.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Review
  6. Article
  7. Review
  8. Human mutation · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 4 countries.

Andrew DauberCincinnati Center for Growth Disorders, Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
María T Muñoz-CalvoDepartment of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús Instituto de Investigación La Princesa Universidad Autónoma de Madrid, Madrid, Spain Program of Pediatric Obesity, CIBEROBN Instituto de Salud Carlos III, Madrid, Spain.
Vicente BarriosDepartment of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús Instituto de Investigación La Princesa Universidad Autónoma de Madrid, Madrid, Spain Program of Pediatric Obesity, CIBEROBN Instituto de Salud Carlos III, Madrid, Spain.
Horacio M DomenéCentro de Investigaciones Endocrinológicas "Dr. César Bergadá" (CEDIE), CONICET, FEI, División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
Soren KloverprisDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Clara Serra-JuhéGenetics Unit, Universitat Pompeu Fabra Hospital del Mar Research Institute (IMIM) & CIBERER. Instituto de Salud Carlos III, Barcelona, Spain.
Vardhini DesikanDepartment of Pediatrics, Division of Pediatric Endocrinology, New York Medical College, Valhalla NY, USA.
Jesús PozoDepartment of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús Instituto de Investigación La Princesa Universidad Autónoma de Madrid, Madrid, Spain Program of Pediatric Obesity, CIBEROBN Instituto de Salud Carlos III, Madrid, Spain.
Radhika MuzumdarDivision of Endocrinology, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Gabriel Á Martos-MorenoDepartment of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús Instituto de Investigación La Princesa Universidad Autónoma de Madrid, Madrid, Spain Program of Pediatric Obesity, CIBEROBN Instituto de Salud Carlos III, Madrid, Spain.
Federico HawkinsDepartment of Endocrinology, Hospital Universitario 12 de Octubre Universidad Complutense de Madrid, Madrid, Spain.
Héctor G JasperCentro de Investigaciones Endocrinológicas "Dr. César Bergadá" (CEDIE), CONICET, FEI, División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
Cheryl A ConoverDivision of Endocrinology, Mayo Clinic, Rochester, MN, USA.
Jan FrystykMedical Research Laboratory, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Shoshana YakarDepartment of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, USA.
Vivian HwaCincinnati Center for Growth Disorders, Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Julie A ChowenDepartment of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús Instituto de Investigación La Princesa Universidad Autónoma de Madrid, Madrid, Spain Program of Pediatric Obesity, CIBEROBN Instituto de Salud Carlos III, Madrid, Spain.
Claus OxvigDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Ron G RosenfeldOregon Health and Science University, Portland, OR, USA STAT5 LLC, Los Altos, CA, USA.
Luis A Pérez-JuradoGenetics Unit, Universitat Pompeu Fabra Hospital del Mar Research Institute (IMIM) & CIBERER. Instituto de Salud Carlos III, Barcelona, Spain.
Jesús ArgenteDepartment of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús Instituto de Investigación La Princesa Universidad Autónoma de Madrid, Madrid, Spain Program of Pediatric Obesity, CIBEROBN Instituto de Salud Carlos III, Madrid, Spain jesus.argente@uam.es.
Instituto de Salud Carlos III · ESAarhus University · DKCincinnati Children's Hospital Medical Center · USHospital Infantil Universitario Niño Jesús · ESAarhus University Hospital · DKCentre for Biomedical Network Research on Rare Diseases · ESChildren's Hospital of Pittsburgh · USConsejo Nacional de Investigaciones Científicas y Técnicas · ARHospital General de Niños Ricardo Gutierrez · ARMayo Clinic in Arizona · USNew York Medical College · USNew York University · USOregon Health & Science University · USUniversidad Autónoma de Madrid · ESUniversidad Complutense de Madrid · ES

Funding

Roles of STAT5b in IGF-I Production and Human GrowthR01HD078592 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI HWA, VIVIAN · 2014 to 2018
$1.7M
Central Role for Osteocytes in Integration of Endocrine Signals During GrowthR01DK100246 · NIDDK · NEW YORK UNIVERSITY · PI YAKAR, SHOSHANA · 2014 to 2017
$1.3M
Rare Genetic Variants as Novel Causes of Idopathic or Syndromic Short StatureK23HD073351 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI DAUBER, ANDREW NAHUM · 2012 to 2016
$664k
NICHD NIH HHS K23 HD073351NICHD NIH HHS R01 HD078592NIDDK NIH HHS R01 DK100246
6 · The paper itself

Abstract

Mutations in multiple genes of the growth hormone/IGF-I axis have been identified in syndromes marked by growth failure. However, no pathogenic human mutations have been reported in the six high-affinity IGF-binding proteins (IGFBPs) or their regulators, such as the metalloproteinase pregnancy-associated plasma protein A2 (PAPP-A2) that is hypothesized to increase IGF-I bioactivity by specific proteolytic cleavage of IGFBP-3 and -5. Multiple members of two unrelated families presented with progressive growth failure, moderate microcephaly, thin long bones, mildly decreased bone density and elevated circulating total IGF-I, IGFBP-3, and -5, acid labile subunit, and IGF-II concentrations. Two different homozygous mutations in PAPPA2, p.D643fs25* and p.Ala1033Val, were associated with this novel syndrome of growth failure. In vitro analysis of IGFBP cleavage demonstrated that both mutations cause a complete absence of PAPP-A2 proteolytic activity. Size-exclusion chromatography showed a significant increase in IGF-I bound in its ternary complex. Free IGF-I concentrations were decreased. These patients provide important insights into the regulation of longitudinal growth in humans, documenting the critical role of PAPP-A2 in releasing IGF-I from its BPs.

Indexed as

MutationAdolescentChildChild, PreschoolDwarfismFemaleHumansInsulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor ILongitudinal StudiesMalePregnancy-Associated Plasma Protein-AYoung AdultInsulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IPAPPA2 protein, humanPregnancy-Associated Plasma Protein-Abonedelayed growthgrowth hormoneIGF‐binding proteinsIGF bioavailability

Identifiers

PMID26902202
PMCPMC4818753
OpenAlexW2280446205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.